Peridot Acquisition Corp. Class A PDAC 深 滬
已收盤 08-10 16:00:00 美东时间
11.23
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 11.23
- 總市值 4.21亿
- 52周最高 125.92
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 70.48
- 委 比 0.00%
- 總股本 3750.00万
- 歷史最高 125.92
- 量 比 0
- 振 幅 0.00%
- 歷史最低 70.48
- 每 手 1
- 風險率 0.15%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- USA News Group News Commentary – Federal budget cuts have put pressure...
08-15 00:22
Elicio Therapeutics Publishes Follow-Up Data From Phase 1 AMPLIFY-201 Study In Nature Medicine
At extended median follow-up of 19.7 months, median overall survival ("OS") increased from 16.33 to 28.94 monthsClinical efficacy correlated with the magnitude of T cell responses specific to mutant-KRAS ("mKRAS")
08-12 20:11
A Glimpse Into The Expert Outlook On Cardiff Oncology Through 4 Analysts
4 analysts have shared their evaluations of Cardiff Oncology (NASDAQ:CRDF) duri...
08-06 21:02
Elicio's Pancreatic Cancer Vaccine Trial Clears Key Review, Moves Ahead Without Changes
Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company"))), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that following the
08-05 19:11
针对“癌症之王”，劲方医药宣布小分子新药获FDA快速通道资格
（来源：求实药社） 7月25日，劲方医药宣布GFH375/VS-7375（口服KRAS G12D抑制剂）获得美国FDA授予快速通道资格，用于KRAS G12D突...
07-25 12:09
Purple Biotech's Chief Executive Officer Gil Efron Issued A Letter To Shareholders Highlighting The Company's Scientific Progress, Operational Execution, And Strategic Milestones During 1H 2025
2025 First Half HighlightsCM24 (α-CEACAM1 monoclonal antibody)Our Phase 2 dataset demonstrated strong objective response rates (ORR) in biomarker-enriched subgroups of second line PDAC patients, as outlined below. These
07-24 19:29
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 23, 2025 /PRNewswire/ -- USA News Group News Commentary – Cancer diagnoses are climbing fastest...
07-23 21:26
Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities
Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER. BC, July 16, 2025 /PRNewswire/ -- As lawmakers weigh potential cuts to scientific research funding, the ...
07-17 06:51
Otsuka’s PTSD therapy draws efficacy concerns at FDA ahead of AdCom meeting
The FDA staffers on Wednesday cited efficacy issues related to a combination regimen involving brexpiprazole, an antipsychotic medication developed by Otsuka Pharma (OTCPK:OTSKY) and H. Lundbeck (OTCP...
07-17 02:25
